FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

4 37	•														
Name and Address of Reporting Person* Bigora Sian			2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106			3. Date of Earliest Transaction (Month/Day/Year) 08/05/2021						X Officer (give title below) Other (specify below) Chief Development Officer				elow)		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
HANOVER, MD 21076										1,					
(City	r)	(State)	(Zip)		Tabl	le I - Nor	ı-Deri	vative S	ecurities	Acqui	ired, Dispo	osed of, or I	Beneficially	Owned	
1.Title of S (Instr. 3)	Title of Security 2. Transaction Date (Month/Day/Year				(Instr. 8)		4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)			Beneficially Owned Following Reported Transaction(s) Ownership Form:		Ownership Form:	7. Nature of Indirect Beneficial		
				(Month/Day/Yo	ear)	Code	V	Amoun	(A) or (D)	Price	(Instr. 3 a	(I)		or Indirect	Ownership (Instr. 4)
Common	Stock		08/05/2021			A		7,601	A	<u>(1)</u>	395,418			D	
Common Stock									133,353		I	I	By CorLyst,		
															LLC
		separate line for		Derivative Secu	rities	Acquire	Perso conta the fo	ons whained ir	respor this for plays a	m are curre eficial	not requ		ormation pond unle	ss	1474 (9-02)
Reminder:	Report on a s		Table II - I	Derivative Secu	rities warr	Acquire	Perso conta the fo ed, Dis	ons whained ir orm dis	respor this for plays a f, or Ben ible secur	m are curre eficial	e not requ ntly valid ly Owned	ired to res	pond unle	ss r.	1474 (9-02)
Reminder:	Report on a s	3. Transaction	Table II - I (a 3A. Deemed Execution Dat (any)	Derivative Secu	5. Nu of De Se Ac (A Di of (Ir	Acquire rants, op	Perso conta the fo ed, Dis tions, 6. Da and E	ons whained ir	o respor this for plays a of f, or Ben ible secun isable n Date	eficial rities) 7. Ti Amo Und Secu	not requ	OMB cont	pond unle	of 10. Owners: Form of Derivati Security Direct (or Indire	11. Natur of Indire Beneficie Ownersh (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Bigora Sian C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076			Chief Development Officer			

Signatures

/s/ Sian Bigora by Michael B. Kirwan, as Attorney-in-Fact	08/09/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting of time-based restricted shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.